Novel patient cell-based HTS assay for identification of small molecules for a lysosomal storage disease

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Geng, Haifeng ^a   Whiteley, Grace ^b   Ribbens, Jameson ^a   Zheng, Wei ^b   Southall, Noel ^b   Hu, Xin ^b   Marugan, Juan J ^b   Ferrer, Marc ^b   Maegawa, Gustavo H B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROSIDE SULFATASE; VIRUS LARGE T ANTIGEN;

ARTICLE; CELL CULTURE; CELL VIABILITY; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGENERATIVE DISEASE; FIBROBLAST; FLUORESCENCE ANALYSIS; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LYSOSOME STORAGE DISEASE; METACHROMATIC LEUKODYSTROPHY; OPTICAL DENSITY; CELL LINE; ELECTRONICS; FLUORESCENCE; METABOLISM;

CELL LINE, TRANSFORMED; CEREBROSIDE-SULFATASE; COLORIMETRY; FLUORESCENCE; HUMANS; LYSOSOMAL STORAGE DISEASES; MINIATURIZATION;

EID: 83755229176     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029504     Document Type: Article

References (40)

1. An WF, Tolliday N, (2010) Cell-based assays for high-throughput screening. Mol Biotechnol 45: 180-186.
2. Hampton SL, Kinnaird AI, (2010) Genetic interventions in mammalian cells; applications and uses in high-throughput screening and drug discovery. Cell Biol Toxicol 26: 43-55.
3. Smid BE, Aerts JM, Boot RG, Linthorst GE, Hollak CE, (2010) Pharmacological small molecules for the treatment of lysosomal storage disorders. Expert Opin Investig Drugs 19: 1367-1379.
4. Meikle PJ, Hopwood JJ, Clague AE, Carey WF, (1999) Prevalence of lysosomal storage disorders. JAMA 281: 249-254.
5. Grabowski GA, Hopkin RJ, (2003) Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annu Rev Genomics Hum Genet 4: 403-436.
6. Maegawa GH, Tropak M, Buttner J, Stockley T, Kok F, et al. (2007) Pyrimethamine as a Potential Pharmacological Chaperone for Late-onset Forms of GM2 Gangliosidosis. J Biol Chem 282: 9150-9161.
7. Maegawa GH, Tropak MB, Buttner JD, Rigat BA, Fuller M, et al. (2009) Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 284: 23502-23516.
8. Beck M, (2010) Emerging drugs for lysosomal storage diseases. Expert Opin Emerg Drugs 15: 495-507.
9. Bernier V, Lagace M, Bichet DG, Bouvier M, (2004) Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab 15: 222-228.
10. Tropak MB, Blanchard JE, Withers SG, Brown ED, Mahuran D, (2007) High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones. Chem Biol 14: 153-164.
11. Zheng W, Padia J, Urban DJ, Jadhav A, Goker-Alpan O, et al. (2007) Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci U S A 104: 13192-13197.
12. Motabar O, Shi ZD, Goldin E, Liu K, Southall N, et al. (2009) A new resorufin-based alpha-glucosidase assay for high-throughput screening. Anal Biochem 390: 79-84.
13. Mu TW, Ong DS, Wang YJ, Balch WE, Yates JR 3rd, et al. (2008) Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134: 769-781.
14. Gieselmann V, (2008) Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options. Acta Paediatr Suppl 97: 15-21.
15. Hasilik A, Neufeld EF, (1980) Biosynthesis of lysosomal enzymes in fibroblasts. Synthesis as precursors of higher molecular weight. J Biol Chem 255: 4937-4945.
16. Fratantoni JC, Hall CW, Neufeld EF, (1968) Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 162: 570-572.
17. Neufeld EF, (1989) Natural history and inherited disorders of a lysosomal enzyme, beta-hexosaminidase. J Biol Chem 264: 10927-10930.
18. Monti E, Preti A, Novati A, Aleo MF, Clemente ML, et al. (1992) Uptake and metabolism of a fluorescent sulfatide analogue in cultured skin fibroblasts. Biochim Biophys Acta 1124: 80-87.
19. Baum H, Dodgson KS, Spencer B, (1959) The assay of arylsulphatases A and B in human urine. Clin Chim Acta 4: 453-455.
20. Harzer K, Stinshoff K, Mraz W, Jatzkewitz H, (1973) The patterns of arylsulphatases A and B in human normal and metachromatic leucodystrophy tissues and their relationship to the cerebroside sulphatase activity. J Neurochem 20: 279-287.
21. Lavery P, Brown MJ, Pope AJ, (2001) Simple absorbance-based assays for ultra-high throughput screening. J Biomol Screen 6: 3-9.
22. Zuck P, O'Donnell GT, Cassaday J, Chase P, Hodder P, et al. (2005) Miniaturization of absorbance assays using the fluorescent properties of white microplates. Anal Biochem 342: 254-259.
23. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, et al. (2006) Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A 103: 11473-11478.
24. Walkley SU, (2009) Pathogenic cascades in lysosomal disease-Why so complex? J Inherit Metab Dis 32: 181-189.
25. Chambers C, Smith F, Williams C, Marcos S, Liu ZH, et al. (2003) Measuring intracellular calcium fluxes in high throughput mode. Comb Chem High Throughput Screen 6: 355-362.
26. Li X, Shen F, Zhang Y, Zhu J, Huang L, et al. (2007) Functional characterization of cell lines for high-throughput screening of human neuromedin U receptor subtype 2 specific agonists using a luciferase reporter gene assay. Eur J Pharm Biopharm 67: 284-292.
27. Yarrow JC, Totsukawa G, Charras GT, Mitchison TJ, (2005) Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. Chem Biol 12: 385-395.
28. Eggert US, Kiger AA, Richter C, Perlman ZE, Perrimon N, et al. (2004) Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets. PLoS Biol 2: e379.
29. Furuya T, Momoi T, Suzuki Y, Sato H, Yamaguchi N, (1985) Establishment of human fibroblast cell lines with lysosomal enzyme deficiency by transformation with origin-minus SV40 DNA. J Inherit Metab Dis 8: 143-144.
30. Leinekugel P, Michel S, Conzelmann E, Sandhoff K, (1992) Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 88: 513-523.
31. Gort L, Coll MJ, Chabas A, (1999) Identification of 12 novel mutations and two new polymorphisms in the arylsulfatase A gene: haplotype and genotype-phenotype correlation studies in Spanish metachromatic leukodystrophy patients. Hum Mutat 14: 240-248.
32. Rauschka H, Colsch B, Baumann N, Wevers R, Schmidbauer M, et al. (2006) Late-onset metachromatic leukodystrophy: genotype strongly influences phenotype. Neurology 67: 859-863.
33. Poeppel P, Habetha M, Marcao A, Bussow H, Berna L, et al. (2005) Missense mutations as a cause of metachromatic leukodystrophy. Degradation of arylsulfatase A in the endoplasmic reticulum. FEBS J 272: 1179-1188.
34. Hodder P, Mull R, Cassaday J, Berry K, Strulovici B, (2004) Miniaturization of intracellular calcium functional assays to 1536-well plate format using a fluorometric imaging plate reader. J Biomol Screen 9: 417-426.
35. Schroter T, Minond D, Weiser A, Dao C, Habel J, et al. (2008) Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-kinase II (ROCK-II). J Biomol Screen 13: 17-28.
36. Williams KP, Scott JE, (2009) Enzyme assay design for high-throughput screening. Methods Mol Biol 565: 107-126.
37. Simeonov A, Jadhav A, Thomas CJ, Wang Y, Huang R, et al. (2008) Fluorescence spectroscopic profiling of compound libraries. J Med Chem 51: 2363-2371.
38. Gribbon P, Sewing A, (2003) Fluorescence readouts in HTS: no gain without pain? Drug Discov Today 8: 1035-1043.
39. Fluharty AL, Fluharty CB, Bohne W, von Figura K, Gieselmann V, (1991) Two new arylsulfatase A (ARSA) mutations in a juvenile metachromatic leukodystrophy (MLD) patient. Am J Hum Genet 49: 1340-1350.
40. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.